Atea sticks it out with failed COVID-19 antiviral but also raids Merck's store room for hepatitis C drug

Atea Pharmaceuticals is still determined to get its COVID-19 antiviral through clinical trials, but without a partner to collaborate with, the biotech is also raiding Merck's store room to make a play in a different indication.